Suk-Woo Oh
Chief Operating Officer bij SCM LIFESCIENCE CO., LTD.
Profiel
Suk-Woo Oh is the founder of SMART Biosciences, Inc.,Keymo Ltd.
He is currently the Chief Operating Officer at SCM Lifescience Co., Ltd.
He was previously the Managing Director at Roberts Mitani LLC and the General Counsel at Daewoong Pharmaceutical Co., Ltd.
Mr. Oh has a graduate degree from The California State University and a graduate degree from the University of Notre Dame The Law School.
Actieve functies van Suk-Woo Oh
Bedrijven | Functie | Begin |
---|---|---|
SCM LIFESCIENCE CO., LTD. | Chief Operating Officer | - |
Eerdere bekende functies van Suk-Woo Oh
Bedrijven | Functie | Einde |
---|---|---|
Roberts Mitani LLC
Roberts Mitani LLC Investment Banks/BrokersFinance Founded in 1992, Roberts Mitani LLC is an independent broker/dealer headquartered in New York City. The firm provides a full array of trading and execution services for their clients. They do not provide any internal research | Corporate Officer/Principal | - |
Keymo Ltd. | Founder | - |
SMART Biosciences, Inc.
SMART Biosciences, Inc. BiotechnologyHealth Technology At SMART Biosciences they are engaged in a coordinated effort to discover and develop novel small-molecule therapeutics to treat major age-related illnesses, including Alzheimer's disease and various forms of cancer. Since its beginning in 2005, as a spin-off of Columbia University, they have been working to address significant unmet therapeutic needs in these large and rapidly growing markets. Through its affiliation with Columbia University, SMART holds exclusive worldwide licenses to valuable intellectual property. Its scientists have identified several novel targets in two therapeutic areas that have the potential for new treatments in: Alzheimer's disease--a novel lipid target that modulates levels of neurotoxic beta-amyloid in the brain, Cancer--novel targets that modulate p53 stability, increasing tumor-cell sensitivity to cytotoxic and radiation therapies. They believe its intellectual property and scientific rationale for future compound discovery offers a compelling opportunity for commercialization. SMART is led by management and scientific advisory teams comprised of preeminent professionals distinguished in the worlds of academic science, pharmaceutical discovery, business/corporate development, finance and intellectual property law. The SMART Biosciences leadership team brings scientific rigor, business leadership, and innovation experience to its endeavors. Its discovery and development strategy employs a unique-to-the-industry collaborative network of advanced business, academic and R&D interests throughout the United States and Asia. | Chief Executive Officer | - |
DAEWOONG PHARMACEUTICAL CO., LTD | General Counsel | - |
Opleiding van Suk-Woo Oh
The California State University | Graduate Degree |
University of Notre Dame The Law School | Graduate Degree |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
Beursgenoteerde bedrijven | 2 |
---|---|
DAEWOONG PHARMACEUTICAL CO., LTD | Health Technology |
SCM LIFESCIENCE CO., LTD. | Health Technology |
Bedrijven in privébezit | 3 |
---|---|
Roberts Mitani LLC
Roberts Mitani LLC Investment Banks/BrokersFinance Founded in 1992, Roberts Mitani LLC is an independent broker/dealer headquartered in New York City. The firm provides a full array of trading and execution services for their clients. They do not provide any internal research | Finance |
SMART Biosciences, Inc.
SMART Biosciences, Inc. BiotechnologyHealth Technology At SMART Biosciences they are engaged in a coordinated effort to discover and develop novel small-molecule therapeutics to treat major age-related illnesses, including Alzheimer's disease and various forms of cancer. Since its beginning in 2005, as a spin-off of Columbia University, they have been working to address significant unmet therapeutic needs in these large and rapidly growing markets. Through its affiliation with Columbia University, SMART holds exclusive worldwide licenses to valuable intellectual property. Its scientists have identified several novel targets in two therapeutic areas that have the potential for new treatments in: Alzheimer's disease--a novel lipid target that modulates levels of neurotoxic beta-amyloid in the brain, Cancer--novel targets that modulate p53 stability, increasing tumor-cell sensitivity to cytotoxic and radiation therapies. They believe its intellectual property and scientific rationale for future compound discovery offers a compelling opportunity for commercialization. SMART is led by management and scientific advisory teams comprised of preeminent professionals distinguished in the worlds of academic science, pharmaceutical discovery, business/corporate development, finance and intellectual property law. The SMART Biosciences leadership team brings scientific rigor, business leadership, and innovation experience to its endeavors. Its discovery and development strategy employs a unique-to-the-industry collaborative network of advanced business, academic and R&D interests throughout the United States and Asia. | Health Technology |
Keymo Ltd. |